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Summary: Heparan sulphate proteoglycans are major components of the glomerular basement membrane and play a
key role in their molecular organization and function. Moreover, their presence is essential for the maintenance of the
selective permeability of the glomerular basement membrane. Recently, we have isolated and characterized a novel,
small basement membrane associated heparan sulphate proteoglycan from human aorta and kidney. Using specific
monoclonal antibodies we have shown that the novel heparan sulphate proteoglycan is predominantly located in the
glomerular basement membrane, to a lesser extent in the basement membrane of tubuli, and also in the mesangium.
Turnover or, in the course of kidney diseases, degradation of heparan sulphate proteoglycan from glomerular basement
membranes may lead to urinary excretion of heparan sulphate proteoglycan. Therefore, changes in the structure and
function of glomerular basement membranes may be directly detected by measuring the excretion of a component of
this basement menbrane, e. g. heparan sulphate proteoglycan into urine. Here we describe the establishment of an en-
zyme immunoassay for the sensitive detection of the novel, small heparan sulphate proteoglycan in urine. In this assay
the specific monoclonal antibody 1F10/B8, which recognizes a core protein epitope, was used to detect the polyanionic
heparan sulphate proteoglycan bound to the surface of a cationic charge modified microtitre plate. This assay allows
the sensitive and specific detection of the small heparan sulphate proteoglycan, which is released from the glomerular
basement membrane into urine during normal turnover and also in the course of kidney diseases.
Introduction
Heparan sulphate proteoglycans are major components
of the glomerular basement membranes and play a key
role in their molecular organization and function (re-
viewed in 1. c. (1 —3)). The presence of heparan sulphate
proteoglycans is essential for the maintenance of the se-
lective permeability of the glomerular basement mem-
brane (3—5). Loss of the anionic sites provided by the
heparan sulphate proteoglycans is associated with pro-
teinuria and has been observed in a number of nephropa-
thies (3 — 10). Such a loss might occur as the result of
reduced synthesis, enhanced turnover, or degradation of
heparan sulphate proteoglycans. However, the exact
mechanism of this process is not well understood.
Recently, we have isolated and characterized a novel,
small basement membrane associated heparan sulphate
proteoglycan from human aorta and kidney. Using spe-
cific monoclonal antibodies we have shown that this he-
paran sulphate proteoglycan is predominantly located in
the glomerular basement membrane, and to a lesser ex-
tent in the basement membrane of tubuli and also in
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the mesangium. Partial amino acid sequence data clearly
show that this heparan sulphate proteoglycan is distinct
from the large basement membrane associated heparan
sulphate proteoglycan (perlecan) (11).
Measurement of heparan sulphate proteoglycans, released
from the glomerular basement membrane during normal
turnover and also in the course of kidney diseases and
excreted into urine, might be a sensitive marker for the de-
tection of alterations of the glomerular basement mem-
brane. In the present study we describe the development
of an enzyme immunoassay, using the specific monoclo-
nal antibody 1F10/B8, which recognizes a core protein
epitope of the small heparan sulphate proteoglycan,
which allows the sensitive detection of the novel small he-
paran sulphate proteoglycan in urine.
Materials and Methods
Reagents
Sephadex G-25, Sepharose Q, Protein-G-Sepharose, TSK G 4000
SW column (7.5 mm X 300 mm), TSK G SWP guard-column (7.5
mm X 75 mm) and preformed gels for SDS poly-acrylamide gel
electrophoresis (4-15% gradient) were obtained from Pharmacia/
LKB (Freiburg, Germany). Hydroxylapatite and Zeta-Probe blot-
ting membrane were obtained from Bio-Rad (Munich, Germany).
Polyvinylidenfluoride blotting membranes (Fluorotrans) were
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purchased from Pall (Dreieich, Germany). High molecular mass
standards, 3-[3-(cholamido-propyl)-dimethylamino]-1 -propane-
sulphonate (CHAPS), benzamidine hydrochloride, 6-amino-hexa-
noic acid, phenylmethylsulphonyl fluoride and N-ethylmaleinimide
were purchased from Sigma (Deisenhofen, Germany). Diamino-
benzamidine-tetrahydrochloride was from Serva (Heidelberg, Ger-
many), o-phenylenediamine and peroxidase-conjugated rabbit-anti-
mouse-Ig-antiserum were from DAKO (Kopenhagen, Denmark)
and peroxidase-conjugated goat-antiserum against mouse-Ig were
from Dianova (Hamburg, Germany). Heparinase (heparin lyase;
EC 4.2.2.T)2) and heparitinase (heparan sulfate lyase EC 4.2.2.S)2)
were obtained from Seikagaku (Tokio, Japan). Sulphosuccinimi-
dyl-6-(biotinamido)-hexanoate (NHS-LC-biotin) was from Pierce
(Munich, Germany). Polyethylene glycol 1500 (PEG 1500) and
trypsin (EC 3.4.21.4) were from Boehringer Mannheim (Mann-
heim, Germany). Dulbecco's modified Eagle's medium was from
GIBCO, BRL (Eggenstein, Germany). Casein was from Sigma
(Munich, Germany). All remaining reagents were of analytical
grade (Merck, Darmstadt, Germany).
Methods
Small basement membrane associated heparan sulphate
proteoglycan from human aorta and kidney
The novel, small heparan sulphate proteoglycan was isolated from
human aorta and kidney and characterized biochemically and im-
munochemically as described elsewhere (11 — 13). Briefly: Pro-
teoglycans were extracted by 4 mol/1 guanidine hydrochloride, 0.05
mol/1 sodium acetetate, (pH 5.8) containing 5 g/1 CHAPS and the
protease inhibitors benzamidine hydrochloride (0.005 mol/1), 6-
aminohexanoic acid (0.1 mol/1), phenylmethylsulphonyl fluoride
(0.005 mol/1), N-ethylmaleimide (0.01 mol/1), and EDTA (0.05
mol/1). The 4 mol/1 guanidine hydrochloride extract was equili-
brated with 0.05 mol/1 Tris, 0.05 mol/1 sodium acetate buffer (pH
5.8) containing 7 mol/1 urea, 0.05 mol/1 NaCl, 0.05 mol/1 LiCl, 2 g/1
CHAPS and protease-inhibitors (0.001 mol/1 N-ethylmaleimide,
0.002 mol/1 benzamidine hydrochloride and 0.001 mol/1 phenyl-
methylsulphonyl fluoride) by size-exclusion chromatography on
Sephadex G-25. Heparan sulphate proteoglycan was isolated by
anion-exchange chromatography on Sepharose Q (Pharmacia/LKB,
Freiburg, Germany) and further purified by hydroxylapatite chro-
matography. Heparan sulphate proteoglycan was characterized by
SDS-PAGE prior to and after digestion with glycosaminoglycan-
specific enzymes. For immunoblots the small basement membrane
associated heparan sulphate proteoglycan from human kidney was
submitted to SDS-PAGE on preformed 4-15% gradient gels
(Pharmacia Phast system, Pharmacia/LKB) and blotted to polyvi-
nylidenfluoride membranes (Fluorotrans, Pall) by diffusion (13).
After blocking of non-specific binding sites, heparan sulphate pro-
teoglycan was detected by the specific monoclonal antibodies
1F10/B8 or 2E2/B5 and a peroxidase-conjugated goat-anti-mouse-
IgG antibody (Dianova) and 3,3'-diaminobenzidine tetra-hydro-
chloride as substrate.
Whereas heparan sulphate proteoglycan isolated from aorta re-
vealed an MT distribution of > 200000-80000, for the small he-
paran sulphate proteoglycan from kidney an MT distribution of
160000—30000 was found. The size of the core proteins was de-
termined to be Mr24000 and Mr 22000 for aorta and kidney,
respectively. The monoclonal antibody 1F10/B8 (see below) recog-
nizes both core proteins. However, small heparan sulphate proteo-
glycans from the kidney and aorta can be discriminated according
to their different size, which is mainly due to differences in their
glycosaminoglycan chain moieties. The size of the heparan sul-
phate proteoglycan isolated from urine was in the Mt range of
160000-30000, indicating that it is derived mainly from the kid-
ney. Partial amino acid sequence data clearly show that this he-
paran sulphate proteoglycan is distinct from the large basement
membrane associated heparan sulphate proteoglycan (perlecan).
2) Enzymes
Heparinase (heparin lyase EC 4.2.2.7)
Heparitinase (heparan sulfate lyase EC 4.2.2.8)
Cloning and sequencing of the core protein of this heparan sulphate
proteoglycan are presently in progress.
Monoclonal antibodies
Monoclonal antibodies were raised in mice according to a modified
protocol of the basic outline of K hler and Milstein (14). Briefly:
100 μg of the small basement membrane associated heparan sul-
phate proteoglycan in a volume of 300 μΐ were mixed with an
equal volume ofFreund's complete adjuvant and injected intraperi-
toneally and subcutaneously into 8 week old BALB/c female mice.
After 6 weeks the mice received booster injections of the antigen
in Freund's incomplete adjuvant and a final injection 3 days before
fusion. Serum titers of pre-immune and immune sera were deter-
mined with a semiquantitative slot blot enzyme immunoassay (see
below). Spleen cells of the mouse with the highest serum titre were
fused with the BALB/c myeloma X63-Ag8/653 with polyethylene
glycol. Cells were plated in 96-well plates in Dulbeccos's modified
Eagle's medium containing foetal calf serum, volume fraction 0.1
and hypoxanthine-aminopterine-thymidine mixture. Hybridoma su-
pernatants were tested by the slot blot enzyme immunoassay. Hy-
bridomas showing a positive reaction were cloned and subcloned
by limiting dilution.
Screening and characterization of monoclonal antibodies
Supematants were tested for specific antibody against the small
basement membrane associated heparan sulphate proteoglycan using
a slot blot enzyme immunoassay on a Zeta Probe membrane (Bio-
Rad). Briefly: 50 ng per slot of the small basement membrane associ-
ated heparan sulphate proteoglycan preparation were incubated for
10 min at room temperature on a Zeta Probe membrane. After block-
ing of the membrane with BLOTTO (20 g/1 dry milk powder in phos-
phate-buffered saline) for 2 h, 200 μΐ of hybridoma supernatants
were incubated for 4 h at room temperature. Bound antibodies were
detected by a peroxidase-conjugated second antibody from goat and
diaminobenzidine/H2O2 as substrate. Subclass determination of the
specific monoclonal antibodies was done by an enzyme immuno-
assay using subclass specific antisera (Dianova, Hamburg, Ger-
many). Purification of monoclonal antibodies from cell culture su-
pernatants was done by protein G affinity chromatography according
to the manufacturers instructions (Pharmacia/LKB).
Heparan sulphate proteoglycan enzyme immunoassay
Using one of the monoclonal antibodies (1F10/B8) against the
small heparan sulphate proteoglycan from human aorta, a sensitive
enzyme immunoassay for heparan sulphate proteoglycan was de-
veloped. In principle in this assay the polyanionic heparan sulphate
proteoglycan from the sample is bound on a cationic charge modi-
fied 96-well microtitre plate (Greiner, N rtingen, Germany).
Antigen-containing samples (100 μΐ/well) diluted 1 : 10 in 0.05
mol/1 sodium phosphate buffer (pH 4.5), containing 0.5 g/1 Tween
20 were incubated on a cationic charge modified 96-well microtitre
plate (kindly provided by Greiner, N rtingen, Germany) for 60 min
at room temperature. After washing with 0.1 mol/1 KH2PO4/
K2HPO4 (pH 6.5), non-specific binding sites were blocked by 10
g/1 casein (Sigma) in phosphate-buffered saline (200 μΐ/well, 60
min, 37 °C. All incubations were carried out in a humidified atmo-
sphere. Bound heparan sulphate proteoglycan was detected by the
heparan sulphate proteoglycan specific monoclonal antibody 1F10/
B8. The specific antibody (100 μΐ/well), diluted appropriately in
blocking solution, was allowed to bind for 120 min at room tem-
perature. To remove unbound antibody, wells were washed 5 times
(200 μΐ/well of 0.1 mol/1 KH2PO4/K2HPO4 buffer, pH 6.5). Bound
antibody was detected by the use of a second peroxidase-labelled
polyclonal goat anti-mouse antiserum (Dianova). Unbound second
antibody was removed by washing 5 times with 0.1 mol/1 citrate/
citric acid pH 5.O.
Substrate solution (100 μΐ) was added to the wells (8 mg o-pheny-
lenediamine dissolved in 12 ml 0.1 mol/1 citrate/citric acid pH 5.0
and 5 μΐ Η2Ο2 (300 g/kg)). Colour development was stopped by
addition of 0.5 mol/1 H2SO4 (100 μΐ/well). The plates were read
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using an ELISA plate reader (SLT, Overath, Germany) at a wave-
length of 492 nm; absorbance at 690 nm was used for back-
ground subtraction.
For heparan sulphate proteoglycan excreted into urine, data were
expressed either as g/l of heparan sulphate proteoglycan or as
heparan sulphate proteoglycan/creatinine excretion ratio (mg/mol
creatinine). All samples were measured at least in duplicate. No
inhibition of binding was observed in this assay when other poly-
anionic molecules such as heparin or keratan sulphate proteogly-
cans were added in control experiments.
Results and Discussion
Heparan sulphate proteoglycans are major components of
the glomerular basement membranes and are essential for
the maintenance of their selective permeability (reviewed
in 1. c. (1 -5)). Loss of the anionic sites provided by the
heparan sulphate proteoglycans is associated with pro-
teinuria and has been observed in a number of nephropa-
thies (3-10). Different types of heparan sulphate pro-
teoglycans have been described in basement membranes
(1,2, 15-18) but the involvement of these different he-
paran sulphate proteoglycans, and especially of the novel,
small heparan sulphate proteoglycan in the glomerular se-
lective permeability has not yet been clarified.
The aim of the present study was to develop an enzyme
immunoassay which allows the sensitive detection of the
small heparan sulphate proteoglycan excreted into urine
and to analyze whether changes of the structure and
function of glomerular basement membranes can be de-
tected by measurement of the excretion of a component
of this basement membrane, e. g. heparan sulphate pro-
teoglycan, into urine. However, an important question
was wether the heparan sulphate proteoglycan excreted
into urine is derived only from the kidney. This question
was addressed by comparison of the different heparan
sulphate proteoglycans.
Comparison of the small basement membrane
associated heparan sulphate proteoglycan
isolated from human aorta and kidney and
from urine
Heparan sulphate proteoglycans isolated from human
aorta and kidney by several Chromatographie steps and
from a sample of urine (which was concentrated, but
without further purification) were submitted to SOS-
PAGE on an 8—25% gradient gel and subsequently blot-
ted onto a positively-charged nylon membrane. Immu-
nochemical detection was performed using the heparan
sulphate proteoglycan specific monoclonal antibody
1F10/B8. Figure 1 clearly shows that the relative molec-
ular mass distribution of heparan sulphate proteoglycan
from urine is comparable to that from human kidney,
with an Mr of 160000-30000. In contrast, the small
heparan sulphate proteoglycan from aorta has an Mr dis-
tribution of > 200000-80000, indicating that the he-
paran sulphate proteoglycan found in urine is derived
from the kidney. Furthermore, the selective permeability
of the intact glomerular basement membrane effectively
presents the excretion of highly negatively charged
molecules, such as heparan sulphate proteoglycan, from
the aorta with an Mr distribution of > 200000-80000.
Therefore the excreted heparan sulphate proteoglycan in
normal subjects is most likely released from the glomer-
ular basement membrane and not from other sources,
e. g. other basement membranes such as the aortal base-
ment membrane. This is also supported by the failure to
detect the large basement membrane associated heparan
sulphate proteoglycan (perlecan) in the urine (£.
Schleicher, personal communication).
Development of an enzyme immunoassay
specific for a core protein epitope of the
small basement membrane associated heparan
sulphate proteoglycan from human kidney
Small heparan sulphate proteoglycan isolated from hu-
man aorta was used for immunization of mice. A series
of more than 20 monoclonal antibodies was obtained.
Two of these monoclonal antibodies (1F10/B8 and 2E2/
B5) were selected for further characterization and subse-
quently used for the development of the enzyme
immunoassay. To determine the specificity of these anti-
bodies, native and enzymatic deglycosylated heparan
sulphate proteoglycan were submitted to SDS-PAGE
and Western blotting. The epitopes, recognized by the
monoclonal antibodies 1F10/B8 and 2E2/B5, were not
influenced by enzymatic deglycosylation of the heparan
sulphate proteoglycan (data not shown), indicating that
20-»
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Fig. 1 Western blot of heparan sulphate proteoglycan from hu-
man aorta and kidney and from urine
Heparan sulphate proteoglycan isolated from human kidney (1),
urine (2), and aorta (3) was submitted to SDS-PAGE on an 8-25%
gradient gel and subsequently blotted onto a positively charged
nylon membrane. Immunochemical detection was performed using
the monoclonal antibody 1F10/B8. (The negative staining phenom-
enon in the urine sample is caused by urinary albumin which pre-
vents immobilization of heparan sulphate proteoglycan on the ny-
lon membrane; indicated by an arrow). For comparison, heparan
sulphate proteoglycan isolated from human aorta (3) is given.
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these antibodies recognize epitopes present on the core
protein of the small heparan sulphate proteoglycan.
Different approaches to establishing a sandwich
immunoassay, using several of the monoclonal antibod-
ies against the small heparan sulphate proteoglycan,
failed. This was most probably due to the fact that the
antibodies used were specific for the relatively small
core protein (Mr 22000-24000). As a sandwich assay
depends on either repetitive epitopes or at least expres-
sion of two different epitopes on the antigen, steric hin-
drance might have occurred. Therefore, in a second at-
tempt we have tried to establish a competitive antigen
inhibition assay, since this type of assay does not depend
on the expression of repetitive epitopes or at least two
different epitopes. In this type of assay a constant
amount of biotin-labelled antigen is added to the sample,
and competes with the unlabelled antigen present in the
sample for binding to an immobilized antibody. Biotin-
labelled antigen bound to the antibody can then be de-
tected by the use of streptavidin-peroxidase. However,
this approach was also unsuccessful. A main reason was
that biotinylation of the antigen seemed to alter the bind-
ing affinity of the antibody.
Therefore, we finally decided to establish an antigen
binding assay in which the strongly negatively charged
polyanionic heparan sulphate proteoglycan is bound to
the surface of a cationic charge modified 96-well micro-
titre plate. Bound antigen can then be detected by the
specific monoclonal antibody 1F10/B8 and a peroxi-
dase-conjugated goat-anti-mouse-Ig antibody. This ap-
proach was successful. An example of the standard bind-











Fig. 2 Standard binding curve obtained with the monoclonal anti-
body 1F10/B8
Increasing amounts of small basement membrane associated he-
paran sulphate proteoglycan (0.032 to 9.6 ng/well) were allowed
to bind for l h to the cationized surface of the microtitre plate.
Bound heparan sulphate proteoglycan was detected using a second
peroxidase-conjugated polyclonal goat-anti-mouse-Ig antiserum as
described under Material and Methods.
sulphate proteoglycan concentrations in the range of
0.32-9.6 ng/well can be measured, corresponding to a
concentration of 32—9600 μg/l in the samples. Non-spe-
cific binding was successfully overcome in this assay by
using 0.5 g/1 Tween-20 in the sample buffer. No inhibi-
tion of binding was observed in the assay when other
polyanionic molecules such as heparin or keratan sul-
phate (up to 5 mg/1 heparin and 25 mg/1 keratan sul-
phate) were added (data not shown). The influence of
excreted proteins, which frequently occurs in protein-
uria, was analyzed by the addition of albumin to the
samples up to a concentration of 5 g/1. Up to this con-
centration of albumin no inhibition of heparan sulphate
proteoglycan binding was observed at higher concentra-
tions of heparan sulphate proteoglycan and only a minor
inhibition (< 15%) was observed at concentrations be-
tween 3.2 and 1 ng/well (data not shown). In patients
with a proteinuria exceeding 5 g/1, the glomerular base-
ment membrane is severely damaged with a greatly re-
duced content of heparan sulphate proteoglycan. In these
patients analysis of the excretion of heparan sulphate
proteoglycan will be of limited value.
The reliability of the assay was analyzed with respect
to sensitivity and precision. For the within-run and
between-run imprecision, coefficient of variation (CV)
values of ^ 10% were obtained. The CV values were
determined for heparan sulphate proteoglycan concen-
trations of 3.2 ng/well (n = 10, within-run CV = 4.1%,
between-run CV = 5.6%). Under the conditions de-
scribed the lower detection limit of the assay was about
20 ng/1.
For heparan sulphate proteoglycan excreted into urine,
data were expressed either as μg/l of heparan sulphate
proteoglycan or as a heparan sulphate proteoglycan/cre-
atinine excretion ratio (mg/mol creatinine). The mean
urinary heparan sulphate proteoglycan concentration in
normal control subjects was 28 ± 8 μ§/1 (η = 17). The
mean urinary heparan sulphate proteoglycan/creatinine
excretion ratio in normal control subjects was 3.74
± 1.29 mg/mol. The relatively broad range of individual
heparan sulphate proteoglycan excretion rates might be
due to the influence of exercise on the heparan sulphate
proteoglycan/creatinine excretion ratio. In fact, prelimi-
nary data indicate that the heparan sulphate proteogly-
can/creatinine excretion ratio shows a strong increase
after exercise. Therefore, a standardized exercise proto-
col was developed, which allows the measurement of
the short-term exercise-induced increased excretion of
heparan sulphate proteoglycan under conditions where
de novo synthesis of heparan sulphate proteoglycan
could be excluded. Under these conditions, the exercise-
induced excretion of heparan sulphate proteoglycan
correlated with the content of heparan sulphate proteo-
glycan, as evidenced by immuno-histochemistry (19).
According to these data, heparan sulphate proteoglycan
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excretion in normal subjects most probably reflects turn-
over of heparan sulphate proteoglycan in the glomerular
basement membrane. However, the molecular mecha-
nism of the release of heparan sulphate proteoglycan
from basement membranes remains to be clarified.
Whereas in humans no data are available on the turnover
of basement membrane heparan sulphate proteoglycans,
results from an experimental rat model indicate that he-
paran sulphates in the kidney exhibit a very rapid turn-
over with a half-life in the range of 5—20 hours, when
examined by metabolic labelling and immunoprecipita-
tion (20-22). In contrast, for collagen from glomerular
basement membrane of the rat, a half-life of about 110
days has been found (23).
The assay described in the present report will allow the
sensitive determination of basement membrane associ-
ated heparan sulphate proteoglycan levels in human
urine and the detection of basement membrane alter-
ations in the course of renal diseases. Therefore, devel-
opment of this assay might be an important contribution
to the spectrum of methods currently used for the analy-
sis of proteinuria, such as the measurement of protein
concentrations or analysis of the protein pattern in urine
by SDS-PAGE (24—27). The novel enzyme immuno-
assay may be especially useful in the non-invasive
analysis of basement membrane metabolism and break-
down in renal diseases, in monitoring disease pro-
gression and therapy control.
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